Can we clinically diagnose dementia with Lewy bodies yet?

Translational Neurodegeneration

Volumn 2, Issue 1, 2013, Pages

  Huang, Yue ^a   Halliday, Glenda ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Dementia with Lewy bodies; Diagnosis; Genetics; Pathogenesis; Pathology

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; CHOLINE ACETYLTRANSFERASE; CLOZAPINE; OLANZAPINE; THIORIDAZINE;

AUTOPSY; CLINICAL FEATURE; CLINICAL PRACTICE; COGNITIVE DEFECT; CRITERION VARIABLE; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; DISEASE COURSE; DISEASE SEVERITY; DRUG HYPERSENSITIVITY; HALLUCINATION; HISTOPATHOLOGY; HUMAN; NEUROFIBRILLARY TANGLE; PARASOMNIA; PARKINSONISM; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; RECURRENT DISEASE; REM SLEEP; REVIEW; SENSITIVITY AND SPECIFICITY; VISUAL HALLUCINATION;

EID: 84883604806     PISSN: None     EISSN: 20479158     Source Type: Journal    
DOI: 10.1186/2047-9158-2-4     Document Type: Review

References (78)

1. Okazaki H, Lipkin LE, Aronson SM. Diffuse intracytoplasmic ganglionic inclusions (Lewy type) associated with progressive dementia and quadriparesis in flexion. J Neuropathol Exp Neurol 1961, 20:237-244. 10.1097/00005072-196104000-00007, 13730588.
2. Kosaka K, Yoshimura M, Ikeda K, Budka H. Diffuse type of Lewy body disease: progressive dementia with abundant cortical Lewy bodies and senile changes of varying degree-a new disease?. Clin Neuropathol 1984, 3:185-192.
3. Dickson DW, Davies P, Mayeux R, Crystal H, Horoupian DS, Thompson A, Goldman JE. Diffuse Lewy body disease. Neuropathological and biochemical studies of six patients. Acta Neuropathol 1987, 75:8-15. 10.1007/BF00686786, 3434218.
4. Hansen L, Salmon D, Galasko D, Masliah E, Katzman R, DeTeresa R, Thal L, Pay MM, Hofstetter R, Klauber M, et al. The Lewy body variant of Alzheimer's disease: a clinical and pathologic entity. Neurology 1990, 40:1-8.
5. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996, 47:1113-1124. 10.1212/WNL.47.5.1113, 8909416.
6. McKeith I, Mintzer J, Aarsland D, Burn D, Chiu H, Cohen-Mansfield J, Dickson D, Dubois B, Duda JE, Feldman H, et al. Dementia with Lewy bodies. Lancet Neurol 2004, 3:19-28. 10.1016/S1474-4422(03)00619-7, 14693108.
7. McKeith I. Dementia with Lewy bodies and Parkinson's disease with dementia: where two worlds collide. Pract Neurol 2007, 7:374-382. 10.1136/jnnp.2007.134163, 18024777.
8. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005, 65:1863-1872. 10.1212/01.wnl.0000187889.17253.b1, 16237129.
9. Kosaka K. Kosaka's disease. Shinkei kenkyu no shinpo 2008, 60:13-16.
10. Weisman D, Cho M, Taylor C, Adame A, Thal LJ, Hansen LA. In dementia with Lewy bodies, Braak stage determines phenotype, not Lewy body distribution. Neurology 2007, 69:356-359. 10.1212/01.wnl.0000266626.64913.0f, 17646627.
11. Merdes AR, Hansen LA, Jeste DV, Galasko D, Hofstetter CR, Ho GJ, Thal LJ, Corey-Bloom J. Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies. Neurology 2003, 60:1586-1590. 10.1212/01.WNL.0000065889.42856.F2, 12771246.
12. Fujishiro H, Ferman TJ, Boeve BF, Smith GE, Graff-Radford NR, Uitti RJ, Wszolek ZK, Knopman DS, Petersen RC, Parisi JE, Dickson DW. Validation of the neuropathologic criteria of the third consortium for dementia with Lewy bodies for prospectively diagnosed cases. J Neuropathol Exp Neurol 2008, 67:649-656. 10.1097/NEN.0b013e31817d7a1d, 2745052, 18596548.
13. Walker Z, Jaros E, Walker RW, Lee L, Costa DC, Livingston G, Ince PG, Perry R, McKeith I, Katona CL. Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy. J Neurol Neurosurg Psychiatry 2007, 78:1176-1181. 10.1136/jnnp.2006.110122, 2117602, 17353255.
14. Oinas M, Polvikoski T, Sulkava R, Myllykangas L, Juva K, Notkola IL, Rastas S, Niinisto L, Kalimo H, Paetau A. Neuropathologic findings of dementia with lewy bodies (DLB) in a population-based Vantaa 85+ study. J Alzheim Dis 2009, 18:677-689.
15. Nelson PT, Jicha GA, Kryscio RJ, Abner EL, Schmitt FA, Cooper G, Xu LO, Smith CD, Markesbery WR. Low sensitivity in clinical diagnoses of dementia with Lewy bodies. J Neurol 2010, 257:359-366. 10.1007/s00415-009-5324-y, 2839040, 19795154.
16. Ferman TJ, Boeve BF, Smith GE, Lin SC, Silber MH, Pedraza O, Wszolek Z, Graff-Radford NR, Uitti R, Van Gerpen J, et al. Inclusion of RBD improves the diagnostic classification of dementia with Lewy bodies. Neurology 2011, 77:875-882. 10.1212/WNL.0b013e31822c9148, 3162640, 21849645.
17. Auning E, Rongve A, Fladby T, Booij J, Hortobagyi T, Siepel FJ, Ballard C, Aarsland D. Early and presenting symptoms of dementia with lewy bodies. Dement Geriatr Cogn Disord 2011, 32:202-208. 10.1159/000333072, 22095040.
18. Tiraboschi P, Salmon DP, Hansen LA, Hofstetter RC, Thal LJ, Corey-Bloom J. What best differentiates Lewy body from Alzheimer's disease in early-stage dementia?. Brain 2006, 129:729-735. 10.1093/brain/awh725, 16401618.
19. McKeith IG. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. J Alzheim Dis 2006, 9:417-423.
20. Parkkinen L, Pirttila T, Alafuzoff I. Applicability of current staging/categorization of alpha-synuclein pathology and their clinical relevance. Acta Neuropathol 2008, 115:399-407. 10.1007/s00401-008-0346-6, 2270355, 18297293.
21. Verghese J, Crystal HA, Dickson DW, Lipton RB. Validity of clinical criteria for the diagnosis of dementia with Lewy bodies. Neurology 1999, 53:1974-1982. 10.1212/WNL.53.9.1974, 10599768.
22. McKeith IG. Dementia with Lewy bodies. Br J Psychiatr 2002, 180:144-147.
23. Ferman TJ, Smith GE, Boeve BF, Ivnik RJ, Petersen RC, Knopman D, Graff-Radford N, Parisi J, Dickson DW. DLB fluctuations: specific features that reliably differentiate DLB from AD and normal aging. Neurology 2004, 62:181-187. 10.1212/WNL.62.2.181, 14745051.
24. Lee DR, Taylor JP, Thomas AJ. Assessment of cognitive fluctuation in dementia: a systematic review of the literature. Int J Geriatr Psychiatry 2012, 27:989-998. 10.1002/gps.2823, 22278997.
25. Uchiyama M, Nishio Y, Yokoi K, Hirayama K, Imamura T, Shimomura T, Mori E. Pareidolias: complex visual illusions in dementia with Lewy bodies. Brain 2012, 135:2458-2469. 10.1093/brain/aws126, 3407420, 22649179.
26. Bonanni L, Thomas A, Tiraboschi P, Perfetti B, Varanese S, Onofrj M. EEG comparisons in early Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease with dementia patients with a 2-year follow-up. Brain 2008, 131:690-705. 10.1093/brain/awm322, 18202105.
27. Harding AJ, Broe GA, Halliday GM. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain 2002, 125:391-403. 10.1093/brain/awf033, 11844739.
28. Harding AJ, Lakay B, Halliday GM. Selective hippocampal neuron loss in dementia with Lewy bodies. Ann Neurol 2002, 51:125-128. 10.1002/ana.10071, 11782993.
29. Yamamoto R, Iseki E, Murayama N, Minegishi M, Marui W, Togo T, Katsuse O, Kosaka K, Kato M, Iwatsubo T, Arai H. Correlation in Lewy pathology between the claustrum and visual areas in brains of dementia with Lewy bodies. Neurosci Lett 2007, 415:219-224. 10.1016/j.neulet.2007.01.029, 17275187.
30. Yamamoto R, Iseki E, Murayama N, Minegishi M, Marui W, Togo T, Katsuse O, Kato M, Iwatsubo T, Kosaka K, Arai H. Investigation of Lewy pathology in the visual pathway of brains of dementia with Lewy bodies. J Neurol Sci 2006, 246:95-101. 10.1016/j.jns.2006.02.016, 16624323.
31. Tiraboschi P, Hansen LA, Alford M, Sabbagh MN, Schoos B, Masliah E, Thal LJ, Corey-Bloom J. Cholinergic dysfunction in diseases with Lewy bodies. Neurology 2000, 54:407-411. 10.1212/WNL.54.2.407, 10668703.
32. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994, 44:2308-2314. 10.1212/WNL.44.12.2308, 7991117.
33. Molloy S, McKeith IG, O'Brien JT, Burn DJ. The role of levodopa in the management of dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 2005, 76:1200-1203. 10.1136/jnnp.2004.052332, 1739807, 16107351.
34. Lucetti C, Logi C, Del Dotto P, Berti C, Ceravolo R, Baldacci F, Dolciotti C, Gambaccini G, Rossi G, Bonuccelli U. Levodopa response in dementia with lewy bodies: a 1-year follow-up study. Parkinsonism Relat Disord 2010, 16:522-526. 10.1016/j.parkreldis.2010.06.004, 20615745.
35. Boeve BF, Ferman TJ. Neuropsychological characterization of evolving cognitive decline in idiopathic REM sleep behavior disorder is important, but not easy. Sleep 2011, 34:561-562. 3079933, 21532947.
36. Boot BP, Boeve BF, Roberts RO, Ferman TJ, Geda YE, Pankratz VS, Ivnik RJ, Smith GE, McDade E, Christianson TJ, et al. Probable rapid eye movement sleep behavior disorder increases risk for mild cognitive impairment and Parkinson disease: a population-based study. Ann Neurol 2012, 71:49-56. 10.1002/ana.22655, 3270692, 22275251.
37. Dugger BN, Boeve BF, Murray ME, Parisi JE, Fujishiro H, Dickson DW, Ferman TJ. Rapid eye movement sleep behavior disorder and subtypes in autopsy-confirmed dementia with Lewy bodies. Mov Disord 2012, 27:72-78. 10.1002/mds.24003, 3513369, 22038951.
38. Aarsland D, Perry R, Larsen JP, McKeith IG, O'Brien JT, Perry EK, Burn D, Ballard CG. Neuroleptic sensitivity in Parkinson's disease and parkinsonian dementias. J Clin Psychiatry 2005, 66:633-637.
39. Hassan I. Consultation-liaison psychiatry and prevention of severe neuroleptic sensitivity reactions in dementia with Lewy bodies. Australas Psychiatr 2011, 19:536-537.
40. McKeith I, O'Brien J, Walker Z, Tatsch K, Booij J, Darcourt J, Padovani A, Giubbini R, Bonuccelli U, Volterrani D, et al. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol 2007, 6:305-313. 10.1016/S1474-4422(07)70057-1, 17362834.
41. Klein JC, Eggers C, Kalbe E, Weisenbach S, Hohmann C, Vollmar S, Baudrexel S, Diederich NJ, Heiss WD, Hilker R. Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo. Neurology 2010, 74:885-892. 10.1212/WNL.0b013e3181d55f61, 20181924.
42. Kemp PM, Clyde K, Holmes C. Impact of 123I-FP-CIT (DaTSCAN) SPECT on the diagnosis and management of patients with dementia with Lewy bodies: a retrospective study. Nucl Med Commun 2011, 32:298-302. 10.1097/MNM.0b013e328343d4ec, 21278615.
43. Papathanasiou ND, Boutsiadis A, Dickson J, Bomanji JB. Diagnostic accuracy of (1)(2)(3)I-FP-CIT (DaTSCAN) in dementia with Lewy bodies: a meta-analysis of published studies. Parkinsonism Relat Disord 2012, 18:225-229. 10.1016/j.parkreldis.2011.09.015, 21975260.
44. Kantarci K, Lowe VJ, Boeve BF, Weigand SD, Senjem ML, Przybelski SA, Dickson DW, Parisi JE, Knopman DS, Smith GE, et al. Multimodality imaging characteristics of dementia with Lewy bodies. Neurobiol Aging 2012, 33:2091-2105. 10.1016/j.neurobiolaging.2011.09.024, 22018896.
45. Vemuri P, Simon G, Kantarci K, Whitwell JL, Senjem ML, Przybelski SA, Gunter JL, Josephs KA, Knopman DS, Boeve BF, et al. Antemortem differential diagnosis of dementia pathology using structural MRI: Differential-STAND. Neuroimage 2011, 55:522-531. 10.1016/j.neuroimage.2010.12.073, 3039279, 21195775.
46. Boeve BF, Molano JR, Ferman TJ, Smith GE, Lin SC, Bieniek K, Haidar W, Tippmann-Peikert M, Knopman DS, Graff-Radford NR, et al. Validation of the Mayo Sleep Questionnaire to screen for REM sleep behavior disorder in an aging and dementia cohort. Sleep Med 2011, 12:445-453. 10.1016/j.sleep.2010.12.009, 3083495, 21349763.
47. Chiba Y, Fujishiro H, Iseki E, Ota K, Kasanuki K, Hirayasu Y, Satoa K. Retrospective survey of prodromal symptoms in dementia with Lewy bodies: comparison with Alzheimer's disease. Dement Geriatr Cogn Disord 2012, 33:273-281. 10.1159/000339363, 22722638.
48. Olanow CW, Obeso JA. The significance of defining preclinical or prodromal Parkinson's disease. Mov Disord 2012, 27:666-669. 10.1002/mds.25019, 22508285.
49. Jicha GA, Schmitt FA, Abner E, Nelson PT, Cooper GE, Smith CD, Markesbery WR. Prodromal clinical manifestations of neuropathologically confirmed Lewy body disease. Neurobiol Aging 2010, 31:1805-1813. 10.1016/j.neurobiolaging.2008.09.017, 2891418, 19026468.
50. Dubois B, Burn D, Goetz C, Aarsland D, Brown RG, Broe GA, Dickson D, Duyckaerts C, Cummings J, Gauthier S, et al. Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. Mov Disord 2007, 22:2314-2324. 10.1002/mds.21844, 18098298.
51. Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, Broe GA, Cummings J, Dickson DW, Gauthier S, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007, 22:1689-1707. quiz 1837, 10.1002/mds.21507, 17542011.
52. Barton B, Grabli D, Bernard B, Czernecki V, Goldman JG, Stebbins G, Dubois B, Goetz CG. Clinical validation of Movement Disorder Society-recommended diagnostic criteria for Parkinson's disease with dementia. Mov Disord 2012, 27:248-253. 10.1002/mds.24059, 22162144.
53. Dickson DW, Braak H, Duda JE, Duyckaerts C, Gasser T, Halliday GM, Hardy J, Leverenz JB, Del Tredici K, Wszolek ZK, Litvan I. Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol 2009, 8:1150-1157. 10.1016/S1474-4422(09)70238-8, 19909913.
54. McKeith IG, Rowan E, Askew K, Naidu A, Allan L, Barnett N, Lett D, Mosimann UP, Burn D, O'Brien JT. More severe functional impairment in dementia with lewy bodies than Alzheimer disease is related to extrapyramidal motor dysfunction. Am J Geriatr Psychiatr 2006, 14:582-588.
55. Dickson DW. Neuropathology of non-Alzheimer degenerative disorders. Int J Clin Exp Pathol 2009, 3:1-23. 2776269, 19918325.
56. Wakabayashi K, Matsumoto K, Takayama K, Yoshimoto M, Takahashi H. NACP, a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson's disease. Neurosci Lett 1997, 239:45-48. 10.1016/S0304-3940(97)00891-4, 9547168.
57. Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 2004, 318:121-134. 10.1007/s00441-004-0956-9, 15338272.
58. Braak H, Sastre M, Del Tredici K. Development of alpha-synuclein immunoreactive astrocytes in the forebrain parallels stages of intraneuronal pathology in sporadic Parkinson's disease. Acta Neuropathol 2007, 114:231-241. 10.1007/s00401-007-0244-3, 17576580.
59. Kramer ML, Schulz-Schaeffer WJ. Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J Neurosci 2007, 27:1405-1410. 10.1523/JNEUROSCI.4564-06.2007, 17287515.
60. Jellinger KA. Alpha-synuclein pathology in Parkinson's and Alzheimer's disease brain: incidence and topographic distribution-a pilot study. Acta Neuropathol 2003, 106:191-201. 10.1007/s00401-003-0725-y, 12845452.
61. Walker Z, McKeith I, Rodda J, Qassem T, Tatsch K, Booij J, Darcourt J, O'Brien J. Comparison of cognitive decline between dementia with Lewy bodies and Alzheimer's disease: a cohort study. BMJ Open 2012, 2:e000380. 10.1136/bmjopen-2011-000380, 3330257, 22318660.
62. Halliday GM, Song YJ, Harding AJ. Striatal beta-amyloid in dementia with Lewy bodies but not Parkinson's disease. J Neural Transm 2011, 118:713-719. 10.1007/s00702-011-0641-6, 21479514.
63. Gomperts SN, Rentz DM, Moran E, Becker JA, Locascio JJ, Klunk WE, Mathis CA, Elmaleh DR, Shoup T, Fischman AJ, et al. Imaging amyloid deposition in Lewy body diseases. Neurology 2008, 71:903-910. 10.1212/01.wnl.0000326146.60732.d6, 2637553,2637553, 18794492.
64. Kalaitzakis ME, Walls AJ, Pearce RK, Gentleman SM. Striatal Abeta peptide deposition mirrors dementia and differentiates DLB and PDD from other parkinsonian syndromes. Neurobiol Dis 2011, 41:377-384. 10.1016/j.nbd.2010.10.005, 20951207.
65. Gomperts SN, Locascio JJ, Marquie M, Santarlasci AL, Rentz DM, Maye J, Johnson KA, Growdon JH. Brain amyloid and cognition in Lewy body diseases. Mov Disord 2012, 27:965-973. 10.1002/mds.25048, 22693110.
66. Villemagne VL, Okamura N, Pejoska S, Drago J, Mulligan RS, Chetelat G, O'Keefe G, Jones G, Kung HF, Pontecorvo M, et al. Differential diagnosis in Alzheimer's disease and dementia with Lewy bodies via VMAT2 and amyloid imaging. Neurodegener Dis 2012, 10:161-165. 10.1159/000334535, 22261520.
67. Aarsland D, Ballard CG, Halliday G. Are Parkinson's disease with dementia and dementia with Lewy bodies the same entity?. J Geriatr Psychiatry Neurol 2004, 17:137-145. 10.1177/0891988704267470, 15312277.
68. Woodruff BK, Graff-Radford NR, Ferman TJ, Dickson DW, DeLucia MW, Crook JE, Arvanitakis Z, Brassler S, Waters C, Barker W, Duara R. Family history of dementia is a risk factor for Lewy body disease. Neurology 2006, 66:1949-1950. 10.1212/01.wnl.0000219812.20616.b3, 16801670.
69. Harding AJ, Das A, Kril JJ, Brooks WS, Duffy D, Halliday GM. Identification of families with cortical Lewy body disease. Am J Med Genet B 2004, 128B:118-122.
70. Nishioka K, Wider C, Vilarino-Guell C, Soto-Ortolaza AI, Lincoln SJ, Kachergus JM, Jasinska-Myga B, Ross OA, Rajput A, Robinson CA, et al. Association of alpha-, beta-, and gamma-Synuclein with diffuse lewy body disease. Arch Neurol 2010, 67:970-975. 10.1001/archneurol.2010.177, 20697047.
71. Ohtake H, Limprasert P, Fan Y, Onodera O, Kakita A, Takahashi H, Bonner LT, Tsuang DW, Murray IV, Lee VM, et al. Beta-synuclein gene alterations in dementia with Lewy bodies. Neurology 2004, 63:805-811. 10.1212/01.WNL.0000139870.14385.3C, 1808539, 15365127.
72. Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, Ampuero I, Vidal L, Hoenicka J, Rodriguez O, Atares B, et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 2004, 55:164-173. 10.1002/ana.10795, 14755719.
73. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, et al. alpha-Synuclein locus triplication causes Parkinson's disease. Science 2003, 302:841. 10.1126/science.1090278, 14593171.
74. Higuchi S, Arai H, Matsushita S, Matsui T, Kimpara T, Takeda A, Shirakura K. Mutation in the alpha-synuclein gene and sporadic Parkinson's disease, Alzheimer's disease, and dementia with lewy bodies. Exp Neurol 1998, 153:164-166. 10.1006/exnr.1998.6868, 9743579.
75. El-Agnaf OM, Curran MD, Wallace A, Middleton D, Murgatroyd C, Curtis A, Perry R, Jaros E. Mutation screening in exons 3 and 4 of alpha-synuclein in sporadic Parkinson's and sporadic and familial dementia with Lewy bodies cases. Neuroreport 1998, 9:3925-3927. 10.1097/00001756-199812010-00029, 9875730.
76. Meeus B, Verstraeten A, Crosiers D, Engelborghs S, Van den Broeck M, Mattheijssens M, Peeters K, Corsmit E, Elinck E, Pickut B, et al. DLB and PDD: a role for mutations in dementia and Parkinson disease genes?. Neurobiol Aging 2012, 33:629 e5-629 e18.
77. Mata IF, Samii A, Schneer SH, Roberts JW, Griffith A, Leis BC, Schellenberg GD, Sidransky E, Bird TD, Leverenz JB, et al. Glucocerebrosidase gene mutations: a risk factor for Lewy body disorders. Arch Neurol 2008, 65:379-382. 10.1001/archneurol.2007.68, 2826203, 18332251.
78. Bogaerts V, Engelborghs S, Kumar-Singh S, Goossens D, Pickut B, van der Zee J, Sleegers K, Peeters K, Martin JJ, Del-Favero J, et al. A novel locus for dementia with Lewy bodies: a clinically and genetically heterogeneous disorder. Brain 2007, 130:2277-2291. 10.1093/brain/awm167, 17681982.